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The melanocortin 1 receptor is a G-protein-coupled receptor, described to be expressed on melanomas and melanocytes.
Subsequent RT–PCR studies demonstrated the presence of melanocortin 1 receptor mRNA in other tissues such as pituitary
gland and testis. Previously, we have demonstrated that three HLA-A2 binding nonamer peptides derived from melanocortin
1 receptor can elicit peptide-speciﬁc CTL which can recognize target cells transfected with the melanocortin 1 receptor gene
and MHC class I matched melanoma lines. The potential of targeting melanocortin 1 receptor in therapy and diagnosis will
depend on a preferential expression of this receptor in the majority of primary and metastatic melanomas vs normal tissues.
We tested a panel of melanomas, carcinomas and other cell lines for the presence of melanocortin 1 receptor, using two
monoclonal antibodies. The receptor was detected in 83% of the tested melanoma cell lines but not in other carcinoma lines.
Immunohistochemistry revealed a strong expression of melanocortin 1 receptor in all tested primary and metastatic
melanomas, but also demonstrated low levels of expression in adrenal medulla, cerebellum, liver and keratinocytes. Flow
cytometry studies showed that melanocortin 1 receptor was expressed in in vitro activated monocytes/macrophages and in
the THP-1 monocytic leukaemia line at levels of about 1 in 3 to 1 in 5 of that found in melanomas. Peripheral blood-derived
dendritic cells, also express melanocortin 1 receptor in vitro. This extensive analysis of melanocortin 1 receptor tissue
distribution may be of relevance not only for melanoma immunology, but also for research on the pathogenicity of
inﬂammatory conditions in the skin and neurologic tissues. It remains to be seen if the over-expression of melanocortin 1
receptor in melanomas is sufﬁciently high to allow a ‘therapeutic window’ to be exploited in cancer immunotherapy.
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Alpha-melanocyte stimulating hormone (a-MSH) is a tridecapep-
tide derived from the precursor molecule propiomelanocortin
(POMC) (Eberle, 1988) and is primarily released by the pituitary,
but also by immunocompetent cells (Schauer et al, 1994; Farooqui
et al, 1995; Star et al, 1995). a-MSH is a very potent stimulator of
the pigmentation and differentiation of pigmented cells, including
melanoma cells (Schwahn et al, 2001). POMC derived peptides
have been shown to transmit their signal via G-protein coupled
receptors through the formation of cyclic AMP and activation of
protein kinase C (Friedmann et al, 1990; Ao et al, 1998; Abdel-
Malek et al, 2000). Five different subtypes of melanocortin recep-
tors with different tissue distribution have been described
(Chhajlani and Wikberg, 1992; Mountjoy et al, 1992; Chhajlani
et al, 1993; Gantz et al, 1993a,b). Of these, the melanocortin 1
receptor (MC1R) was originally described to be mainly located
on melanoma and melanocytes (Varga et al, 1976; Tatro et al,
1990; Chhajlani, 1996; Suzuki et al, 1996; Xia et al, 1996). MC1R
was, however, subsequently shown also to be expressed in various
human tissues including human keratinocytes and monocytes
(Chhajlani ans Wikberg, 1992; Rajora et al, 1996; Tho ¨rnwall et
al, 1997; Chakraborty et al, 1999; Curry et al, 2001).
The cloning of genes encoding human melanoma-associated anti-
gens, and the deﬁnition of CTL peptide epitopes derived from these,
has stirred considerable interest among immunologists and clini-
cians. The majority of the characterized melanoma-associated CTL
epitopes are derived from normal, non-mutated proteins. These
include the melanin synthesis associated proteins Melan-A/Mart-1,
gp100, and tyrosinase (Brichard et al, 1993; Coulie et al, 1994;
Kawakami et al, 1994a,b), which encode peptide CTL epitopes
presented by MHC Class I molecules (Brichard et al, 1993; Kawaka-
mi et al, 1994c; Kawakami et al, 1995). These antigens are also
expressed on normal melanocytes in the skin and on melanocyte-
like cells in the retina, and therefore should be regarded as true ‘self’
antigens. CTL reacting with these antigens can often be demon-
strated in patients with advanced melanomas (Brichard et al,
1993; Coulie et al, 1994; Kawakami et al, 1994a,b,c, 1995). These
results have been interpreted as evidence for the breaking of immu-
nological tolerance to normal cellular proteins, perhaps due to
overexpression of these molecules on tumour cells.
Recently, we have demonstrated that three MC1R derived nona-
meric peptides which bind with high- or intermediate afﬁnity to
HLA-A2 can generate peptide speciﬁc CTL from peripheral blood
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www.bjcancer.commononuclear cells (PBMC) of healthy HLA-A2+ donors. These
peptide-speciﬁc CTL could also recognise HLA-A2+ melanoma
cells expressing MC1R, demonstrating that the MC1R derived
peptides are naturally processed and presented by MHC class I
on the surface of melanoma cells (Salazar-Onfray et al, 1997).
The possibility of using MC1R for antibody or T cell based
immunotherapy is dependent on how selectively this receptor is
expressed in melanomas vs normal tissues. Although there is
evidence that MC1R has a broad distribution in various normal
tissues including normal melanocytes, activated macrophages, and
keratinocytes (Chhajlani, 1996; Rajora et al, 1996; Tho ¨rnwall et
al, 1997; Chakraborty et al, 1999; Curry et al, 2001), this assess-
ment is based mainly on qualitative or semi-quantitative
methods. There is experimental and clinical evidence that immu-
notherapy based on administration of monoclonal antibodies or
on speciﬁc tumour vaccines can also have an effect when based
on non-mutated ‘self-proteins’ over-expressed in tumours, such
as non-mutated p53, HER-2/neu, and gp100 (Ropke et al, 1996;
Nagata et al, 1997; Rosenberg et al, 1998; Buchler et al, 2001;
Slamon et al, 2001). This requires however that the level of over-
expression in the tumour, as compared to normal tissue, is high
enough to allow a ‘therapeutic window’, allowing tumour eradica-
tion without excessive autoimmune damage.
In the present study we have analysed several questions relevant
to the potential use of MC1R in immunotherapy of melanomas.
Using ﬂow cytometry based methodology to measure intracellular
levels of MC1R, Western blot and immunohistochemistry, we veri-
fy that this molecule is expressed at high levels in the majority of
melanoma lines and in fresh primary and metastatic melanomas,
and at low levels in certain normal tissues. Of particular interest,
in vitro activated monocytes and dendritic cells (DC) produced
in vitro, also express MC1R although at lower levels than that
observed in melanomas.
MATERIALS AND METHODS
Reagents and chemicals
Biotinylated-a-melanocyte stimulating hormone (Biotinyl-a-MSH)
was purchased from Peninsula laboratory (CA, USA) and non-
labelled a-MSH was purchased from Sigma (Steinheim, Germany).
Phycoerythrin (PE)-conjugated streptavidin was purchased from
Pharmingen (San Diego, USA).
Cell lines
All the melanoma cell lines were established at the Microbiology
and Tumor Biology Center (MTC), Karolinska Institute. The lines
were derived from metastatic lesions of patients treated at Radium-
hemmet, Karolinska Hospital, except the lines 397mel kindly
provided by Dr Y Kawakami NCI, Maryland, USA and FM3Dmel
and FM55.M1mel kindly provided by Dr J Zeuthen, Cancer
Society, Copenhagen, Denmark. DFW is a depigmented melanoma
subline obtained from DFB by limiting dilution. OCM1 and
OCM3 are ocular melanoma lines kindly provided by Dr M Jager
(University of Leiden). OCM5 is an uveal melanoma established at
the Institute of Biomedical Sciences. The T2 line is a TAP-defect
cell line derived from the human T cell leukemia/B cell LCL hybrid
174 (Salter and Cresswell, 1986). C1R-A2 is a class I defective cell
line transfected with HLA-A2 (Zemmour et al, 1992) and C1R-A2/
MC1R is the same line transfected with the MC1R gene. SW480
and SW620 are colon cancer cells from American Type Culture
Collection (ATCC). OVA3507, OVA6906, are colon cancer cells
from American Type Culture Collection (ATCC). OVA3507,
OVA6906, and AK12, are ovarian carcinoma cell lines established
at the MTC. CAOV-4 is an ovarian carcinoma from ATCC.
THP-1 is a monocytic tumour cell line. Cell line 293 is an embry-
onal kidney tumour. BE EBV; BL EBV; 1224 EBV, and 0351 EBV
are LCL lines established at the MTC. The human melanocytes cell
cultures (kindly provided by Dr Luz Maria Mun ˜oz, Faculty of
Medicine, University of Chile) were maintained in Melanocyte
Basal Medium (Sigma, St. Louis, MO, USA).
In vitro culture of monocytes and dendritic cells
Cells from human buffy coats were isolated by separation with
Ficoll-Hypaque (Pharmacia, Sweden). All cells were incubated in
RPMI medium and 10% FCS for 2 h (20610
6 cells ml
71)i na
6 well plate (Costar, Cambridge, MA, USA). Then, non-adherent
cells were removed and the adherent cells were recovered and
prepared for Western blot (fresh monocytes) or left with only
medium (non stimulated monocytes) or stimulated for 48 h with
LPS (2.5 mgm l
71; Sigma Chemical Co., Munich, Germany),
PHA 2 mgm l
71, human recombinant IL-4 (rIL-4) 100 U ml
71
or GM-CSF 100 U ml
71 (generously donated by Shering Plough,
Brinny Co., Ireland). Dendritic cells were isolated in the same
manner as monocytes and incubated with 100 U ml
71 of GM-
CSF and 100 U ml
71 of rIL-4 (also donated from Shering Plough)
for at least 7 days. The medium was replaced every 3–4 days and
the cultures were maintained for 7–9 days. PE-conjugated anti-
CD14 (Beckton-Dickinson, Mountain View, CA, USA) and anti-
CD36 (BD PharMingen, San Diego, CA, USA) were used for the
analysis of cell surface phenotype of monocytes and dendritic cells
respectively. FITC-conjugated CD83 (BD PharMingen, San Diego,
CA, USA) were used to determine the maturation of the DC.
Western blot
Cell pellets from harvested melanoma cell lines (1*10
6 cells) were
suspended in 100 ml lysis buffer (65 mM Tris pH 6.8, 2% SDS,
10% glycerol, 5% mercapto-ethanol, 1% bromophenol blue) and
maintained for 15 min at room temperature. Then, samples were
sonicated by 10 microns for 30 s, warmed at 958C for 5 min and
then centrifuged. Fifteen ml each sample was electrophoresed
through a 12% SDS-polyacrylamide gel. For immunoblots, proteins
were electro transferred onto polyvinyldene ﬂuoride (PVDF)
membrane (Immobilon-P; Millipore Corp., Bedford, MA, USA).
Membranes were blocked in phosphate-buffered saline containing
5% milk (low fat) (PBS/milk 5%). All additional immunostaining
steps were performed in phosphate-buffered saline with 3% milk
(PBS/milk 3%) and washed with phosphate-buffered saline 0.05%
Tween20 (PBS-Tween 0.05%) at room temperature. Filters were
incubated overnight at 48C with the corresponding primary anti-
body; (MP1-1B7 or MP1-1C11) (Tho ¨rnvall et al, 1997), for 1 h
and then with a secondary antibody (horseradish peroxidase-conju-
gated sheep anti-mouse Ig; Amersham, Buckinghamshire, UK) for
30 min. As an internal control a commercial polyclonal antibody
against b-actin was used. Filters were then washed in PBS-Tween
four times and developed with enhanced chemiluminescence
(ECL) system (Amersham, Buckinghamshire, UK).
MC1 receptor binding studies
All procedures were performed according to previously described
methods (Chhajlani et al, 1993). Brieﬂy, 2610
6 cells were collected
and washed with PBS, acidic glycine buffer and RPMI medium.
After transfer of 2610
5 cells per well in a 96-well plate, 10
710 M
biotin-labelled a-MSH were added to each well and the cells were
incubated for 1 h at 378C. Then the cells were washed with cold
PBS once and incubated with PE-labelled streptavidin
(40 mgm l
71) for 30 min at 48C in the dark. As control, cells were
incubated in the presence of PE-streptavidin only. The speciﬁcity
of the biotin-labelled a-MSH binding was evaluated by the addi-
tion of unlabelled a-MSH. The cells were analysed using a
M
o
l
e
c
u
l
a
r
a
n
d
C
e
l
l
u
l
a
r
P
a
t
h
o
l
o
g
y
MC1R expression in melanoma and normal tissues
F Salazar-Onfray et al
415
ã 2002 Cancer Research UK British Journal of Cancer (2002) 87(4), 414–422FACScan ﬂow cytometer (Becton and Dickinson) after ﬁxation
with 1% formaldehyde in PBS.
Intracellular staining
Analysed cells were washed three times with cold PBS, ﬁxed by
10 min incubation with 0.5% paraformaldehyde in PBS, and
washed again with PBS. The cells were permeabilized with 2% digi-
tonin (Sigma, St. Louis, MO, USA) in PBS for 10 min on ice. After
checking the permeability of the cells by trypan blue uptake,
3610
5 cells per well were added to a 96 v-bottom well and incu-
bated with 5 mgm l
71 of mAb MP4-1B7 (anti MC1R) (Tho ¨rnvall
et al, 1997), 2 mgm l
71 of mAb 9.2.27 (Morgan et al, 1981) or
control IgG1 mAb for 30 min on ice. Cells were washed twice with
PBS and incubated 30 min on ice, with a secondary rabbit anti-
mouse Ig PE-conjugated antibody (DAKO, Denmark). After incu-
bation, the cells were washed three times with PBS 0.01% Tween.
Then the cells were ﬁxed again with 1% paraformaldehyde in PBS
containing 0.1% FCS and kept at 48C until analysis by FACS.
Immunohistochemical analysis
Normal and some melanoma tissues were obtained from the
Department of Oncology and Pathology, Karolinska Hospital.
The majority of primary and metastatic melanoma tissues were
obtained from the Department of Pathological Anatomy of the
Hospital of University of Chile. Tissues were ﬁxed in paraformal-
dehyde, embedded in parafﬁn, and sectioned. Immunostaining
was performed using the standard ABC-technique (Dako LSAB
kit, CA, USA). Parafﬁn sections were deparafﬁnized and rehy-
drated. The endogenous peroxidase activity was blocked by
hydrogen peroxide (dissolved in methanol for 30 min). Sections
were incubated with a blocking serum (normal horse serum) for
30 min. Excess of serum was drained and the sections were incu-
bated with the primary antibody (MP1-1B7 or MP1-1C11 anti-
MC1R) (Tho ¨rnvall et al, 1997) at a concentration of 10 mgm l
71.
All incubations were performed overnight at 88C. A biotinylated
anti-mouse IgG was used as secondary antibody and followed by
the ABC-complex. The peroxidase reaction was developed using
3,3-diaminobenzidine (diamino-benzidine tetrahydrochloride,
0.6 mg ml
71 with 0.03% hydrogen peroxide) for 6 min. Counter
staining was not performed in a majority of cases. Haematoxylin
solution (Fluka, Buchs, Switzerland) were used for nuclear staining
in speciﬁed cases. Phosphate buffered saline (pH 7.6) was used for
rinsing between the different steps. The MC1R protein expression
was evaluated according to an arbitrary scale: 1,+,++,+++ on the
basis of the intensity of the immunoreactivity.
Characterization of melanomas
The cells were tested by DAKO EPOS visualisation system (Dako-
patts AB, A ¨lvsjo ¨, Sweden). Brieﬂy, cells were washed with PBS and
then 2610
5 cells per well were ﬁxed with methanol in a 96 v-
bottom well. The cells were then washed with PBS and 50 ml of
horseradish peroxidase (HRP)-coupled mAb HMB45 (Kapur et
al, 1992), S-100 (Cochran et al, 1983) or IgG as control was added
(Dakopatts). After 30 min incubation on ice, the cells were washed
with PBS and 50 ml of the substrate (DAB) (Dakopatts) was
added. Then, the cells were checked in the microscope for colour
reaction.
RESULTS
MC1R is frequently expressed in melanoma cell lines
The speciﬁcity of the mAbs MP1-1B7 and MP1-1C11, previously
described to be speciﬁc for the extracellular domain of MC1R
(Tho ¨rnvall et al, 1997), was conﬁrmed by Western blot analysis
on melanoma lines and EBV immortalized B cell lines (LCL).
Three melanoma cell lines (FMS, OCM3 and OCM1) were positive
for a 37 kD protein, which corresponds to the expected size of
MC1R, while the LCL line C1R-A2 was negative. C1R-A2 transi-
ently transfected with the vector pRC/CMV-hMCIR was positive
for MC1R, conﬁrming the speciﬁcity of the antibody (Figure 1,
upper panel, shown for mAb MP1-1C11, similar results were
observed using the mAb MP1-1B7, data not shown). Western blot
analysis using cryo-preserved melanoma tissues derived from a
metastatic lymph node also demonstrated a strong band corre-
sponding to MC1R in both analysed melanomas, with similar
intensity of expression as that observed in the in vitro cultured
melanoma lines (data not shown).
Intracellular vs cell surface expression of MC1R was also
analysed by ﬂow cytometry on permeabilized and non-permeabi-
lized melanoma and LCL lines. Both the DFB and FM55
melanoma lines showed a weak but signiﬁcant surface expression
of MC1R (Figure 1A,B) while the BL melanoma line and the
C1R-A2 line were completely negative (Figure 1C,D). Permeabi-
lized cells showed considerably stronger signalling than surface
stained ones, and all three tested melanomas, including the cell
surface negative BL line, stained positive with the anti MC1R
mAb (Figure 1A–C), while the C1R-A2 line remained negative
(Figure 1D). The MC1R transfected cell line, C1R-A2/MC1R
showed a major population of MC1R-positive cells, although a
minor population remained negative, probably due to low transfec-
tion efﬁciency and/or incomplete selection (Figure 1E). We
therefore conclude that melanoma lines which do not stain for cell
surface expression can still show intracellular expression of this
protein, the reason why this method of intracellular staining was
used in the subsequent screening of MC1R expression in tumour
lines.
We next performed a more extensive analysis of the intracellu-
lar expression of MC1R in a series of melanomas and carcinomas.
The majority of the melanoma cell lines (20 out of 24), including
three ocular melanomas were found to express this receptor
(Table 1). The MC1R transfected C1R-A2 was as expected
strongly positive for MC1R, while the control C1R-A2 line and
ﬁve other LCL were negative. In addition, two colon carcinomas,
four ovarian carcinomas, and one embryonal kidney line did not
express MC1R.
Then, we compared the expression of MC1R with that of other
commonly expressed melanoma markers. Among the melanoma
lines which were positive for the S-100 mAb (12 out of 13), three
did not express MC1R (FM3D, DL and 397). Conversely, among
the 20 melanomas which expressed MC1R, one (AA) was not posi-
tive for the S-100 marker. None of the tested carcinomas or LCL
was, as expected, positive for the S-100 marker.
Among the melanomas which were positive for the HBM45
mAb (8 out of 13), two did not express MC1R (FM3D and
397). Conversely, two of the HBM45 negative melanomas
expressed MC1R, including the depigmented variant DFW of the
DFB line and the BL line, while one lacked the expression of both
these markers (DL) while still staining positive for the S-100 mAb.
None of the tested carcinomas or LCL was, as expected, positive
for the HBM45 marker.
We also tested the surface expression of the protein recognised
by the melanoma speciﬁc mAb 9.2.27 (Morgan et al, 1981). This
antibody recognises the melanoma-associated chondroitin sulfate
proteoglycan (MCSP) (Pluschke et al, 1996) expressed on melano-
mas (Morgan et al, 1981) and astroglial malignant cells (Schrappe
et al, 1991), and is suggested to play a role during early events of
melanoma cell spreading (Morgan et al, 1981). Only three of the 22
melanomas (DFW, BE and 1206) were negative for this mAb, all
three of which expressed detectable levels of MC1R. Four melano-
mas that were recognised by mAb 9.2.27 were negative for MC1R
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expected, negative for the 9.2.27 marker.
We therefore concluded that MC1R is expressed in the majority
of melanoma cell lines but in none of the tested carcinomas or
LCL, and that the expression of this receptor does not correlate
with any of the other tested melanoma markers.
Immunohistochemical detection of MC1R on
parafﬁn-embedded human tissues
Parafﬁn sections from melanomas or normal tissues were analysed
by immunohistochemistry for MC1R expression. An intense speci-
ﬁc staining was detected in all tested primary melanomas (n=15)
(exempliﬁed in Figure 2A (right panel) and 2B (M)), including
three ocular melanomas. Also, all metastatic melanomas (n=11)
stained strongly positive for MC1R, including metastasis in lymph
nodes (Figure 2C), maxilla (Figure 2D), intestine (Figure 2E),
while the adjacent normal tissues, including the epidermis, dermis,
appendages, and subcutaneous tissue and connective tissues, were
negative. A metastatic melanoma from intestine stained with an
irrelevant Ig was used as negative control (Figure 2F). Melano-
cytes from normal naevi were also negative for MC1R
expression (Figure 2A (left panel)). It was previously described
that human keratinocytes could speciﬁcally bind to a-MSH
(Chakraborty et al, 1999; Curry et al, 2001). We conﬁrmed the
presence of MC1R in keratinocytes (Figure 2B (K)), although
the intensity of staining was weaker than that observed in the
melanoma tissue from the same skin. No differences were detected
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Figure 1 Expression of MC1R in melanoma cell lines. Upper panel: Cell
lines (a) C1R-A2, (b) C1R-A2 neo, (c) C1R-A2/MC1R(1), (d) C1R-A2/
MC1R(2), (e) FMS, (f) OCM1, (g) OCM3 were analysed by Western blot
for the presence of the 37 kD band corresponding to MC1R. Lower panel:
DFB melanoma. (A), FM55 melanoma (B), BL melanoma (C), C1R-A2
LCL line as a negative control (D), and C1R-A2/MC1R (E) were ﬁxed
and incubated with mAb MP4-1B7 directly (left) or after permeabilisation
with digitonin (right) and then stained with PE-conjugate anti-IgG mAbs
and analysed by FACS as described in Materials and Methods. The experi-
ments were performed twice with similar results.
Table 1 Expression of MC1R and other melanoma markers on human
carcinoma cell lines
Cell line Tissue S-100 HBM45 9.2.27 MP1-1B7
DFB Melanoma + + + +
DFW Melanoma + 77 +
FM55.M1 Melanoma + 7 ++
FM3D Melanoma + + + 7
FMS Melanoma + + + +
DL Melanoma + 7 + 7
AA Melanoma 7 ++ +
HF Melanoma + + + +
BL Melanoma + 7 ++
KH Melanoma + + + +
BE Melanoma + + 7 +
AK Melanoma + + + +
397 Melanoma + + + 7
H1264 Melanoma nt nt nt +
ACB Melanoma nt nt nt +
1206 Melanoma nt nt 7 +
0010 Melanoma nt nt + +
1277 Melanoma nt nt + +
7176 Melanoma nt nt + +
8013 Melanoma nt nt + 7
1233 Melanoma nt nt + +
OCM1 Ocular melanoma nt nt + +
OCM3 Ocular melanoma nt nt + +
OCM5 Ocular melanoma nt nt + +
SW480 Colon carcinoma 777 7
SW620 Colon carcinoma 777 7
CAOV-4 Ovarian carcinoma 777 7
AK12 Ovarian carcinoma nt nt 77
OVA3507 Ovarian carcinoma 777 7
OVA6906 Ovarian carcinoma 777 7
THP-1 Monocyte nt nt nt +
293 Embryonal kidney nt nt nt 7
T2 LCL 777 7
C1R-A2 LCL 777 7
C1R-A2(MC1R)
a LCL 777 +
BE EBV LCL 777 7
BL EBV LCL 777 7
1224 EBV LCL nt nt nt 7
0351 EBV LCL nt nt nt 7
MAbs 9.2.27 (surface staining) and MP1-1B7 (intracellular staining) were tested by
ﬂow cytometry. Mabs S-100 and HBM45 were tested by immunochemistry (DAKO
EPOS) as described in Materials and Methods.
aCell line transfected with MC1R gene.
nt=not tested.
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noma tissues.
Using the same method, MC1R was also detected in some cell
components of normal tissues, including adrenal medulla, cerebel-
lum, and liver, although with a considerably lower intensity as
compared to the melanomas (Table 2). A very weak staining, at
the border of being signiﬁcant, was observed in normal appendix,
myocardium, kidney, and myometrium. No speciﬁc staining was
observed in the other 16 analysed normal tissues (Table 2). Since
melanocytes were not stained by MC1R either in situ in the mela-
noma surrounding tissue or in normal naevi, we intend to detect
MC1R expression in short time cultured melanocytes. To perform
this, melanocytes which had been cultured for two passages in vitro
were analysed by immunocytochemistry as described in Materials
and Methods. Both melanocyte tissues analysed here were found
to express MC1R (Figure 3A,B), although the intensity of the stain-
ing was signiﬁcantly lower than that observed in two melanoma
cell lines FM55 (Figure 3C) and FMS (Figure 3D), tested in paral-
lel. Collectively, these results demonstrate that MC1R, although
strongly expressed in melanomas, is also expressed at lower levels
in several normal tissues in situ.
MC1R can also be detected in human in vitro stimulated
monocytes and in a monocytic leukaemia line
The induced expression of MC1R was previously demonstrated on
activated monocytes, using biotin-labelled a-MSH and ﬂow cyto-
metry analysis (Bhardwaj et al, 1997). To conﬁrm the presence of
MC1R in monocytes, we performed Western blot analysis using
the anti MC1R mAb. Also, dendritic cells (DC) described to express
MC1R mRNA (Becher et al, 1999), produced by culture of mono-
cytes in a combination of IL-4 and GM-CSF for 7 days (Sallusto
and Lanzavecchia, 1994), were included in this experiment. We
observed that fresh untreated monocytes did not express detectable
levels of MC1R, while monocytes cultured in medium alone
showed very low expression of this receptor. Furthermore, we
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Figure 2 Immunohistochemical detection of MC1R on primary melanoma tissues, normal keratinocytes and metastatic melanoma tissues. Parafﬁn sec-
tions of primary melanoma tissues and normal skin tissues and metastatic melanoma tissues were stained with mAb MP1-1B7 or IgG control followed by a
biotinylated anti-Ig mAb and developed as described in Materials and Methods. (A) normal naevus 106 (left) and primary melanoma (right) (B) Compar-
ison of the intensity of labelling between a primary melanoma (M) and keratinocytes (K)610. (C) Melanoma inﬁltrated lymph node (MP1-1B7)610. (D)
Maxilar metastasis (MP1-1B7)610. (E) Intestinal metastatic melanoma (MP1-1B7)610, and (F) Intestinal metastatic melanoma (Ig negative control)610. In
panels A, E, and F, nuclear staining was performed using haematoxylin solution.
MC1R expression in melanoma and normal tissues
F Salazar-Onfray et al
418
British Journal of Cancer (2002) 87(4), 414–422 ã 2002 Cancer Research UKconﬁrmed that in vitro culturing of monocytes in IL-4 or GM-CSF
could induce the expression of MC1R (Figure 4). In addition, LPS
and PHA treatment of monocytes could induce MC1R expression
(data not shown). We also investigated the expression of MC1R
in immature DC (CD14-, CD36+, CD83-) (Banchereau and Stei-
mann, 1998; Sauter et al, 2000). We observed that cytokine
induced DC also expressed comparable levels of MC1R as those
observed in cytokine stimulated monocytes (Figure 4).
To further compare the levels of MC1R expression between mela-
nomas and stimulated monocytes, we also performed ﬂow
cytometry analysis of melanomas and monocytes stained with ﬂuor-
escein-conjugated a-MSH. This analysis showed that melanomas
bind ﬁve to seven times more to a-MSH than monocytes cultured
in medium alone (Figure 5A). We also conﬁrmed (Bhardwaj et al,
1997) that monocytes activated by short term culture with LPS or
with GM-CSF alone or in combination with IL-4, showed enhanced
binding of a-MSH (30% for IL-4/GM-CSF and 2–3-fold for GM-
CSF or LPS treated monocytes) as compared to control monocytes
cultured in medium only. The macrophage/monocyte line THP-1
showed the same levels of a-MSH binding as LPS- or cytokine
stimulated monocytes (Figure 5A), conﬁrming the MC1R expres-
sion in this line (Rajora et al, 1996), while an ovarian and a colon
carcinoma (OV3507, SW480) included as controls only bound low
to insigniﬁcant levels of a-MSH.
Next, we compared melanomas and cultured monocytes with
regard to their intracellular content of MC1R, as measured by
ﬂow cytometry of permeabilised cells using the MP1-1B7
mAb. A more pronounced difference in intracellular expression
of MC1R between melanoma lines and cultured monocytes
was detected with this method as compared to that found with
the a-MSH binding method. Thus, stimulated monocytes or the
macrophage line THP-1 showed levels of intracellular MC1R
expression which were 50–20% of that found in the ﬁve mela-
nomas tested (MFI 8 to 18 for stimulated monocytes vs 40 to
85 for the melanomas) (Figure 5B). Fresh monocytes, mono-
cytes cultured in only medium, and the negative control line
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Table 2 Immunoreactivity of MC1R on fresh tissues
Tissue type MC1R-Immunoreactivity
a
Melanoma +++
Mammary tissue 7
Pituitary gland 7
Thyroid+parathyroid tissue 7
Adrenal gland (marrow) ++
Prostate 7
Lymph node 7
Urethra 7
Normal appendix (mucosa) +
Urinary bladder 7
Small intestine 7
Colon 7
Ovary 7
Ovarian tube 7
Cervical mucosa of uterus 7
Endometrium 7
Testis 7
Lung 7
Cerebellum (cortical neurons) +
Myocardium (muscle cells) +
Liver (hepatocytes) +
Kidney (tubular cells) +
Artery, vein and peripheral nerve 7
Myometrium (smooth muscle cells) +
aThe intensity of the immunostaining was evaluated using an arbitrary scale:
7,+,++,+++.
Figure 3 MC1R is overexpressed on melanomas and low expressed in in vitro cultured melanocytes. Melanoma, normal melanocytes cells and control
COS7 cells were cultured on an objective glass overnight, carefully washed with PBS and then ﬁxed with methanol. The ﬁxed cells were stained with mAb
MP1-1B7 or IgG control followed by a biotinylated anti-Ig mAb and developed as described in Materials and Methods. (A and B) Normal melanocytes, (C)
FM55 melanoma line, and (D) FMS melanoma line.
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control mAb (Figure 5B). No signiﬁcant differences between
monocytes or melanoma lines could be detected using an
anti-Vimentine mAb as control (data not shown). Three differ-
ent DC lines cultured for 7–9 days in medium containing GM-
CSF and IL-4 (CD14
7, CD36
+ and CD83
7) showed higher
levels of intracellular MC1R than short time cultured mono-
cytes, comparable to that observed in the low MC1R
expressing BL melanoma cell line. These levels were however
lower (30–50%) than those observed in the high MC1R expres-
sing melanoma lines (DFB, FM55, OCM1 and OCM3) (Figure
5B).
Taken together, this conﬁrms that MC1Ris expressed at signiﬁcant
levels in activated monocytes, DC cells, and macrophage derived
leukaemiacells,althoughtoalesserextentthaninmelanomacelllines.
DISCUSSION
The present report contains several new observations relevant to
the potential use of MC1R in diagnostic and immunotherapy of
melanomas. First, we demonstrate with ﬂow cytometry the broad
distribution of this protein in the majority of melanoma lines,
and that the molecule predominantly is located intracellularly.
Second, we utilise immunohistochemistry and Western blot to
show that also freshly isolated non cultured primary and metastatic
melanomas express this molecule at comparable levels, and conﬁrm
that this molecule is also expressed at low levels in certain normal
in vitro cultured tissues, including activated macrophages and
immature dendritic cells.
Early reports using binding of radiolabelled peptides (Varga et
al, 1976; Tatro et al, 1990; Xia et al, 1996) demonstrated that
the MC1R protein is present on the surface of melanoma cells.
RNA coding for MC1R could also be detected in melanoma cells
and in normal melanocytes (Chhajlani and Wikberg, 1992; Loir
et al, 1999). We found that MC1R is over-expressed in the majority
of the fresh melanoma tissues analysed and also in 20 out of 24
melanoma cell lines but not in carcinoma lines or LCL (Table
1). These results are in line with our earlier ﬁndings based on a
smaller number of tumour lines (Salazar-Onfray et al, 1997).
MC1R is therefore expressed in a proportion of melanomas
comparable to that of the melanocytic glycoprotein gp100, a
protein which has proven a promising target as a melanoma
vaccine (Rosenberg et al, 1998). Furthermore, we found a homoge-
neous staining of MC1R in melanoma metastasis at various
locations, indicating that this protein did not decrease in expres-
sion during tumour progression, while we were unable to detect
MC1R in normal naevi, indicating that at least in situ melanocytes
do not express detectable levels of MC1R (Figure 2A). This is in
line with observations made by others, who could not detect the
MC1R protein in melanocytes from normal skin by immunohisto-
chemistry, but could easily visualize MC1R on skin with melanoma
tumour growth (Xia et al, 1996). This demonstrates that in vivo
melanoma cells have an increased expression of MC1R compared
to normal melanocytes. The difference in levels of MC1R expres-
sion between melanoma cells and normal melanocytes could be
conﬁrmed using short time melanocyte in vitro cultures. The
analysed melanocytes expressed detectable levels of MC1R,
although the melanoma cell lines tested in parallel showed higher
levels of expression (Figure 3).
The comparison between the MC1R speciﬁc mAbs with other
melanoma speciﬁc mAbs commonly used in melanoma diagnosis
showed that although the majority of melanomas were positive
for all three mAbs (S-100, HBM45 and MC1R speciﬁc mAbs),
several tumours expressed a more selective expression pattern lack-
ing one or two of these markers. Interestingly, uveal melanoma, the
most common malignant intraocular tumour in adults, can only be
partially recognised by the three most widely used immunohisto-
chemical reagents for the diagnosis (HMB-45, S-100 and A103
(Melan-A/Mart-1 speciﬁc antibody). These mAbs recognise
between 25–79% of this tumour type (Nicotra et al, 1997;
Heegaard et al, 2000). In comparison, our results revealed a strong
expression of MC1R in all tested primary tissue sections (n=8)
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Figure 4 In vitro stimulated monocytes and immature DC cells express
MC1R. Fresh monocytes, monocytes incubated with medium alone, IL-4
or GM-CSF, and in vitro produced DC were analysed as described in
Materials and Methods by Western blot for the presence of the 37 kD
band corresponding to MC1R. As external control, the samples were
analysed for the expression of b-actin.
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Figure 5 MC1R is overexpressed on melanomas compared to stimu-
lated monocytes. (A) a-MSH binds speciﬁcally to melanoma cells and to
stimulated monocytes. Cells were incubated with biotin-labelled a-MSH
for 1 h, washed, stained with PE-conjugated streptavidin and then analysed
by FACS as described in Materials and Methods. (B) Intracellular expres-
sion of MC1R in melanoma cell lines, the monocytic line THP-1 and stimu-
lated monocytes. Five melanoma cell lines (DFB mel, FM55 mel and BL mel,
OCM1 and OCM3), the macrophage derived line THP-1, 7 day cultured
dendritic cells (DCi) (showed as mean of three lines in B and separately
(DC1, DC2 and DC3 in the histogram) and nonstimulated monocytes
or monocytes incubated with cytokines for 48 h were ﬁxed, permeabilised
and incubated with mAb MP1-1B7. PE-conjugated secondary mAb were
used for detection by FACS as described in Materials and Methods. These
experiments were performed three times each with similar results.
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ingly, MC1R may constitute a valuable complementary marker for
both cutaneous and uveal melanomas to be utilised in diagnosis
and possibly in T cell based immunotherapy.
We have analysed a broad panel of normal tissues by immuno-
histochemistry and compared their expression of MC1R in relation
to melanomas. Low levels of MC1R expression were detected in
adrenal gland, cerebellum and liver. In addition, normal appendix,
myocardium, kidney, and myometrium showed weak staining with
the anti-MC1R mAb (Table 2), as did in vitro activated macro-
phages/monocytes. The immunohistochemical analysis of tissues
from human skin and melanoma metastasis in brain allowed us
to compare in situ the high expression of MC1R in melanomas
with the low expression of this receptor in keratinocytes (Figure
2A). These ﬁndings are in accordance with previous ﬁndings that
low levels of MC1R expression could be detected in the testis,
ovary, and placenta by immunohistochemistry using MC1R speciﬁc
monoclonal antibodies (Tho ¨rnvall et al, 1997). Also, PCR studies
using speciﬁc primers have demonstrated that small amounts of
the MC1R protein are synthesised by tissues other than those of
the melanocytic lineage, including testis and pituitary tissues
(Chhajlani, 1996) similar to what has been observed with gp100
(Brouwenstijn et al, 1997) and MelanA/MART1 (Busam et al,
1998). Taken together, these results show that this molecule is
expressed in several normal tissues including in vitro activated
macrophages of the haematopoietic system, albeit at levels substan-
tially lower than those observed in melanomas.
In light of the relatively broad expression of MC1R in normal
tissues, it is of particular interest that MC1R reactive CTL can be
generated from T cells of healthy individuals (Salazar-Onfray et
al, 1997) and melanoma patients (unpublished observation). In
this context, measuring cell surface levels of MC1R is not an
adequate estimation of the availability of this protein to the T cell
system. Therefore, to quantify the expression of this protein by
ﬂow cytometry we have adapted an intracellular staining protocol
using permeabilised cells. Melanoma lines in which the expression
of these molecules by cell surface staining could not be detected by
the MC1R speciﬁc mAb, including the BL line, still showed strong
intracellular staining in line with previously reported radiolabelled
detection by hormone homologues (Salazar-Onfray et al, 1997).
There is accumulating evidence that a-MSH, which is the ligand
for MC1R, besides being a hormone involved in pigmentation
(Halaban et al, 1983; Kameyama et al, 1989) also plays a crucial
role in the regulation of immune and inﬂammatory reactions
(Blalock, 1999; Luger et al, 2000). One consequence of this could
be that MC1R also could be expressed on haematopoietic cells.
Indeed, stimulated monocytes and macrophage lines were shown
to express MC1R (Star et al, 1995; Bhardwaj et al, 1997). Our data
indicated that while MC1R is not expressed at detectable levels on
fresh monocytes, in vitro stimulation with several cytokines such as
IL-4, GM-CSF, and IL-10 can induce a strong expression of this
receptor (Figures 4 and 5A,B). We also conﬁrmed the presence
of MC1R in activated monocytes/macrophages and in the THP-1
cell line, but at lower levels than those found in melanomas (Figure
5A,B). Melanomas showed two times higher MC1R expression, as
compared to LPS-stimulated monocytes, using a ﬂuorescein
coupled peptide hormone, and up to ﬁve times higher expression
using the speciﬁc mAb MP1-1B7 in intracellular staining assays.
In addition, we found it of interest that long term cultured DC
derived from monocytes expressed signiﬁcant levels of MC1R.
One may speculate if this could reﬂect an activation process in
which MC1R is functionally involved, since several lines of
evidence indicate an important role for MC1R in inﬂammation
(Becher et al, 1999; Blalock, 1999; Luger et al, 2000). However,
although more studies are required to reveal the role of MC1R
in the regulation of the immune response, this extensive analysis
of MC1R tissue distribution may be of relevance not only for mela-
noma immunology but also dermatology, inﬂammation, and
neuroimmunology.
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